To get ahead of what’s expected to be another active year for investment in health technologies and medicine, Hogan Lovells has recruited a Baker McKenzie transactional partner to its corporate and finance practice group in Philadelphia.

Denis Segota, who in recent years has counseled Bayer and argenx in deals, said he will continue to partner with pharmaceutical and biotech companies in buy-side transactions at his new practice. Those include joint ventures, licensing, royalty monetization transactions and others that promote the research, development and commercialization of novel compounds and medical devices.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]